Neo-Sinefrina (Phenylephrine Hydrochloride)

Phenylephrine hydrochloride is a selective alpha‑1 adrenergic agonist. When applied to the nasal lining, it triggers vasoconstriction of the small blood vessels, decreasing blood flow and edema in the nasal passages, which eases congestion.

The appropriate dose of Neo‑Sinefrina is determined by a qualified healthcare professional based on the patient’s age, condition, and response. Users should follow the prescriber’s instructions and the product label without exceeding the recommended frequency.

Safety data for phenylephrine hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Neo‑Sinefrina to weigh potential benefits against risks.

To place an order, submit an enquiry on the Neo‑Sinefrina product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Both phenylephrine (Neo‑Sinefrina) and oxymetazoline are topical alpha‑adrenergic agonists that cause nasal vasoconstriction. Phenylephrine generally has a shorter duration of action and may be preferred for short‑term relief, while oxymetazoline often provides longer‑lasting effects but may carry a higher risk of rebound congestion with prolonged use.

Store Neo‑Sinefrina at room temperature, ideally below 25 °C, in its original packaging. Keep the product away from moisture, direct heat, and sunlight. Ensure the container is tightly closed after each use to maintain product integrity.

Neo‑Sinefrina is applied intranasally. The user inserts the spray tip into one nostril, tilts the head slightly forward, and administers the prescribed number of sprays as directed by a healthcare professional. The same procedure is repeated in the other nostril if required.

Serious adverse events, although rare, include severe hypertension, cardiac arrhythmias, and allergic reactions such as rash, swelling, or anaphylaxis. If any of these symptoms occur, discontinue use immediately and seek medical attention.

Individuals with known hypersensitivity to phenylephrine or any formulation components should avoid Neo‑Sinefrina. It is also contraindicated in patients with uncontrolled hypertension, severe coronary artery disease, or those taking monoamine oxidase inhibitors unless advised by a physician.